Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Saved in:
| Title: | Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. |
|---|---|
| Authors: | Burger, Jan A.1 (AUTHOR), Robak, Tadeusz2 (AUTHOR), Demirkan, Fatih3 (AUTHOR), Bairey, Osnat4 (AUTHOR), Moreno, Carol5 (AUTHOR), Simpson, David6 (AUTHOR), Munir, Talha7 (AUTHOR), Stevens, Don A.8 (AUTHOR), Dai, Sandra9 (AUTHOR), Cheung, Leo W. K.9 (AUTHOR), Kwei, Kevin9 (AUTHOR), Lal, Indu9 (AUTHOR), Hsu, Emily9 (AUTHOR), Kipps, Thomas J.10 (AUTHOR), Tedeschi, Alessandra11 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1375-1386. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 10428194 |
|---|---|
| DOI: | 10.1080/10428194.2021.2020779 |
